Lower Costs in Breast Cancer: How This Affects Treatment

Lower Costs in Breast Cancer: How This Affects Treatment

3 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Courtney Williams, MPH @cphilwil of @ONealCancerUAB explains findings in a new study that results in lower costs and how this affects treatment and clinicians today.

__________

Research from the UAB's O'Neal Comprehensive Cancer Center finds that patients treated outside the recommendations of the NCCN Guidelines had significantly greater direct costs.

A new study by the O'Neal Comprehensive Cancer Center at the University of Alabama in Birmingham (UAB), published in the October 2019 issue of JNCCN— Journal of the National Comprehensive Cancer Network, finds that direct costs for patients with metastatic breast cancer (MBC) increase dramatically when their treatment differs from the NCCN Clinical Practice Guidelines for Oncology (NCCN) recommendations. Previous studies have found that disagreeable care leads to higher overall health care costs[1], but this is the first study to look specifically at the cost burden for patients.

“We thought that it was important to explore potential differences in out-of-pocket costs, since financial toxicity is a growing issue among patients with metastatic breast cancer,” explained Courtney P. Williams, MPH, Division of Hematology and Oncology, O’Neal Comprehensive Cancer Center at UAB. “We found about one in five women received an anticancer treatment that wasn’t listed within the NCCN Guidelines. Those women were responsible for higher out-of-pocket costs—including deductibles, coinsurance, and copayments—in the year following their metastatic breast cancer diagnosis than those receiving an anticancer treatment listed within the guidelines. This finding is especially important for older patients, which made up about 75 percent of our sample, since financial and psychological distress could be worse for patients living on a fixed income.”

The retrospective study used the SEER-Medicare registry to look at the cost of patients of 3,709 women diagnosed with MBC from 2007 to 2013 who survived at least one year after diagnosis. Diagnosis plans have been linked to the version of the Breast Cancer NCCN Guidelines ® available at the exact date of diagnosis. Due to NCCN's regular guideline revisions, the concept of guideline-concordant treatment varied depending on the date.

The average post-diagnosis patient cost for the year was $5,171 for treatment that fit the current NCCN recommendations, compared to $7,421 for care that deviated from them. Overtreatment and undertreatment, as described in the guidelines, eventually resulted in higher costs for patients.

Read here: https://www.oncologytube.com/video/nccn-recommendations-for-metastatic-breast-cancer-lowers-costs-for-patients-according-to-the-new-study-

Up Next Autoplay
EZH2 in Triple Negative Breast Cancer: What's Next in Research? @Ramon_Parsons @IcahnMountSinai
EZH2 in Triple Negative Breast Cancer: What's Next in Research? @Ramon_Parsons @IcahnMountSinai
Category: Breast Cancer
2 Views
Mount Sinai Health System 1 week
EZH2 in Triple Negative Breast Cancer @Ramon_Parsons @IcahnMountSinai
EZH2 in Triple Negative Breast Cancer @Ramon_Parsons @IcahnMountSinai
Category: Breast Cancer
1 Views
Mount Sinai Health System 1 week
SOHPIA Study in Metastatic Breast Cancer #SABCS19 @UCSFMedicine
SOHPIA Study in Metastatic Breast Cancer #SABCS19 @UCSFMedicine
Category: Breast Cancer
31 Views
ash 3 weeks
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
Category: Breast Cancer
17 Views
Cancer-News 3 weeks
Prognostic Marker in Operable Breast Cancer: How This Affects Clinicians? #SABCS19
Prognostic Marker in Operable Breast Cancer: How This Affects Clinicians? #SABCS19
Category: Breast Cancer
6 Views
ash 3 weeks
Prognostic Marker in Operable Breast Cancer #SABCS19
Prognostic Marker in Operable Breast Cancer #SABCS19
Category: Breast Cancer
22 Views
admin 3 weeks
The FLEX Real World Data #SABCS19 @BaptistHealthSA
The FLEX Real World Data #SABCS19 @BaptistHealthSA
Category: Breast Cancer
26 Views
admin 3 weeks
Agendia Presents New Data at #SABCS19 in Breast Cancer
Agendia Presents New Data at #SABCS19 in Breast Cancer
Category: Breast Cancer
7 Views
admin 3 weeks
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage...
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage...
Category: Breast Cancer
12 Views
Cancer-News 1 month
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
18 Views
cancernewsupdate 1 month